[Recombinant immunotoxin for cancer therapy: current status and prospective].
Nagata
S
S
Laboratory of Molecular Biology, National Cancer Institute, National Institute of Health, USA. nagatas@pop.nci.nih.gov
D000818:Animals; D000912:Antibodies, Neoplasm; D002986:Clinical Trials as Topic; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008024:Ligands; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014118:Toxins, Biological
D000912:Antibodies, Neoplasm; D000922:Immunotoxins; D008024:Ligands; D011994:Recombinant Proteins; D014118:Toxins, Biological